33CS30_148422; Swiss Inflammatory Bowel Disease Cohort Study; large nested project; large nested project; Eosinophilic esophagitis; Swiss Inflammatory Bowel Disease Cohort Study; Outcomes research; 33CS30_148422; large nested project (SIBCS)
Dellon Evan (2018), Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference., in Gastroenterology
Greuter Thomas, Safroneeva Ekaterina, Bussmann Christian, Biedermann Luc, Vavricka Stephan R., Katzka David A., Schoepfer Alain M., Straumann Alex (2018), Maintenance Treatment of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-Up Period in Adult Patients, in Clinical Gastroenterology and Hepatology
Schoepfer Alain, Blanchard Carine, Dawson Heather, Lucendo Alfredo, Mauro Aurelio, Ribi Camillo, Safroneeva Ekaterina, Savarino Edoardo V., Penagini Roberto (2018), Eosinophilic esophagitis: latest insights from diagnosis to therapyEosinophilic esophagitis: latest insights, in Annals of the New York Academy of Sciences
Safroneeva Ekaterina, Saner Catherine, Rossel Jean-Benoît, Golay Delphine, Pittet Valérie, Godat Sébastien, Diem Stefan, Aepli Patrick, Sawatzki Mikael, Borovicka Jan, Burgmann Konstantin, Juillerat Pascal, Netzer Peter, Sendensky Alexander, Hruz Petr, Girardin Marc, Biedermann Luc, Greuter Thomas, Vavricka Stephan, Michetti Pierre, Mueller Christoph, Straumann Alex, Schoepfer Alain M. (2018), Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS), in Inflammatory Intestinal Diseases
, 2(3), 163-170.
Schoepfer Alain M, Simko Audrey, Bussmann Christian, Safroneeva Ekaterina, Zwahlen Marcel, Greuter Thomas, Biedermann Luc, Vavricka Stephan, Godat Sébastien, Reinhard Antoine, Saner Catherine, Maye Hugo, Sempoux Christine, Brunel Christophe, Blanchard Carine, Simon Dagmar, Simon Hans-Uwe, Straumann Alex (2018), Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms, in The American Journal of Gastroenterology
, 113(3), 348-357.
Ma Chris (2018), Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review., in Clinical Gastroenterology and Hepatology
Safroneeva Ekaterina, Straumann Alex, Schoepfer Alain M. (2018), Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis, in Gastrointestinal Endoscopy Clinics of North America
, 28(1), 35-45.
Schoepfer Alain M., Straumann Alex, Safroneeva Ekaterina (2018), Pharmacologic Treatment of Eosinophilic Esophagitis, in Gastrointestinal Endoscopy Clinics of North America
, 28(1), 77-88.
Cheng Katherine, Gupta Sandeep K., Kantor Susanna, Kuhl Jonathan T., Aceves Seema S., Bonis Peter A., Capocelli Kelley E., Carpenter Christina, Chehade Mirna, Collins Margaret H., Dellon Evan S., Falk Gary W., Gopal-Srivastava Rashmi, Gonsalves Nirmala, Hirano Ikuo, King Eileen C., Leung John, Krischer Jeffrey P., Mukkada Vincent A., Schoepfer Alain, Spergel Jonathan M., Straumann Alex, Yang Guang-Yu, Furuta Glenn T., et al. (2017), Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), in Translational Science of Rare Diseases
, 2(3-4), 141-155.
Simon Dagmar, Straumann Alex, Schoepfer Alain M., Simon Hans-Uwe (2017), Current concepts in eosinophilic esophagitis, in Allergo Journal International
, 26(7), 258-266.
Vavricka Stephan R., Safroneeva Ekaterina, Schoepfer Alain (2017), Eosinophile Oesophagitis, in Therapeutische Umschau
, 74(6), 309-315.
Greuter Thomas, Bussmann Christian, Safroneeva Ekaterina, Schoepfer Alain M, Biedermann Luc, Vavricka Stephan R, Straumann Alex (2017), Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept, in The American Journal of Gastroenterology
, 112(10), 1527-1535.
Vicari Alain P., Schoepfer Alain M., Meresse Bertrand, Goffin Laurence, Léger Olivier, Josserand Soheila, Guégan Nicolas, Yousefi Shida, Straumann Alex, Cerf-Bensussan Nadine, Simon Hans-Uwe, Chvatchko Yolande (2017), Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis, in mAbs
, 9(6), 927-944.
Blanchard C., Simon D., Schoepfer A., Straumann A., Simon H.-U. (2017), Eosinophilic esophagitis: unclear roles of IgE and eosinophils, in Journal of Internal Medicine
, 281(5), 448-457.
Lucendo Alfredo J, Molina-Infante Javier, Arias Ángel, von Arnim Ulrike, Bredenoord Albert J, Bussmann Christian, Amil Dias Jorge, Bove Mogens, González-Cervera Jesús, Larsson Helen, Miehlke Stephan, Papadopoulou Alexandra, Rodríguez-Sánchez Joaquín, Ravelli Alberto, Ronkainen Jukka, Santander Cecilio, Schoepfer Alain M, Storr Martin A, Terreehorst Ingrid, Straumann Alex, Attwood Stephen E (2017), Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults, in United European Gastroenterology Journal
, 5(3), 335-358.
Dellon Evan S., Collins Margaret H., Bonis Peter A., Leung John, Capocelli Kelley E., Dohil Ranjan, Falk Gary W., Furuta Glenn T., Menard-Katcher Calies, Gupta Sandeep K., Hirano Ikuo, Hiremath Girish S., Kagalwalla Amir F., Wershil Barry K., Liacouras Chris A., Muir Amanda B., Mukkada Vincent A., Putnam Philip E., Schoepfer Alain M., Straumann Alex, Wo John M., Yang Guang-Yu, Rothenberg Marc E., Gonsalves Nirmala (2016), Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders, in Clinical Gastroenterology and Hepatology
, 14(12), 1842-1844.
Schoepfer A., Safroneeva E., Straumann A. (2016), How to measure disease activity in eosinophilic esophagitisHow to measure disease activity in EoE, in Diseases of the Esophagus
, 29(8), 959-966.
Molina-Infante Javier, Schoepfer Alain M, Lucendo Alfredo J., Dellon Evan S (2016), Eosinophilic esophagitis: What can we learn from Crohn’s disease?, in United European Gastroenterology Journal
, 5(6), 762-772.
Moawad Fouad J., Cheng Edaire, Schoepfer Alain, Al-Haddad Sahar, Bellizzi Andrew M., Dawson Heather, El-Zimaity Hala, Guindi Maha, Penagini Roberto, Safrooneva Ekaterina, Chehade Mirna (2016), Eosinophilic esophagitis: current perspectives from diagnosis to managementReview on eosinophilic esophagitis, in Annals of the New York Academy of Sciences
, 1380(1), 204-217.
Ishihara Shunji, Kinoshita Yoshikazu, Schoepfer Alain (2016), Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis: Common Mechanisms and Differences between East and West, in Inflammatory Intestinal Diseases
, 1(2), 63-69.
Schoepfer Alain, Safroneeva Ekaterina, Straumann Alex (2016), Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies, in Digestive Diseases
, 34(5), 462-468.
Straumann A., Blanchard C., Radonjic-Hoesli S., Bussmann Ch., Hruz P., Safroneeva E., Simon D., Schoepfer A. M., Simon H.-U. (2016), A new eosinophilic esophagitis (EoE)-like disease without tissue eosinophilia found in EoE families, in Allergy
, 71(6), 889-900.
Simon D., Cianferoni A., Spergel J. M., Aceves S., Holbreich M., Venter C., Rothenberg M. E., Terreehorst I., Muraro A., Lucendo A. J., Schoepfer A., Straumann A., Simon H.-U. (2016), Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity, in Allergy
, 71(5), 611-620.
Straumann Alex, Schoepfer Alain (2016), Positioning of dilation in eosinophilic oesophagitisTherapy, in Nature Reviews Gastroenterology & Hepatology
, 13(4), 192-194.
Schoepfer Alain, Straumann Alex, Safroneeva Ekaterina (2016), Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia, in Current Treatment Options in Gastroenterology
, 14(1), 51-60.
Safroneeva Ekaterina, Straumann Alex, Coslovsky Michael, Zwahlen Marcel, Kuehni Claudia E., Panczak Radoslaw, Haas Nadine A., Alexander Jeffrey A., Dellon Evan S., Gonsalves Nirmala, Hirano Ikuo, Leung John, Bussmann Christian, Collins Margaret H., Newbury Robert O., De Petris Giovanni, Smyrk Thomas C., Woosley John T., Yan Pu, Yang Guang-Yu, Romero Yvonne, Katzka David A., Furuta Glenn T., Gupta Sandeep K., et al. (2016), Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis, in Gastroenterology
, 150(3), 581-590.e4.
Molina-Infante Javier, Bredenoord Albert J, Cheng Edaire, Dellon Evan S, Furuta Glenn T, Gupta Sandeep K, Hirano Ikuo, Katzka David A, Moawad Fouad J, Rothenberg Marc E, Schoepfer Alain, Spechler Stuart J, Wen Ting, Straumann Alex, Lucendo Alfredo J (2016), Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis, in Gut
, 65(3), 524-531.
Bussmann Christian (2016), Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis, in Endoscopy
Giriens B., Yan P., Safroneeva E., Zwahlen M., Reinhard A., Nydegger A., Vavricka S., Sempoux C., Straumann A., Schoepfer A. M. (2015), Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study, in Allergy
, 70(12), 1633-1639.
Safroneeva E., Coslovsky M., Kuehni C. E., Zwahlen M., Haas N. A., Panczak R., Taft T. H., Hirano I., Dellon E. S., Gonsalves N., Leung J., Bussmann C., Woosley J. T., Yan P., Romero Y., Furuta G. T., Gupta S. K., Aceves S. S., Chehade M., Straumann A., Schoepfer A. M. (2015), Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity, in Alimentary Pharmacology & Therapeutics
, 42(8), 1000-1010.
Schoepfer Alain (2015), Diagnostic approach to eosinophilic oesophagitis: Pearls and pitfalls, in Best Practice & Research Clinical Gastroenterology
, 29(5), 783-792.
Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated condition with a current prevalence of about 1 / 2,000 inhabitants in industrialized countries. Untreated eosinophil-predominant inflammation leads to esophageal remodeling with stricture formation and consecutive food bolus impactions with the inherent risks of esophageal perforation. The optimal long-term therapeutic strategy still needs to be defined. Until recently, no standardized instruments for measuring disease activity existed. Since EoE activity was assessed using different non-validated instruments, discrepancies between severity of symptoms and biologic measures have been described in some, but not in other studies. As such, endpoints for clinical trials and natural history studies could not be defined, and no specific therapies for EoE management have been approved by regulatory authorities in United States and Europe. Furthermore, different stakeholders do not come to an agreement on the therapeutic endpoints to be assessed in clinical trials and observational studies. Under the leadership of the applicants, the international EoE Activity Index (EEsAI) study group developed and validated instruments (questionnaires) that determine EoE symptom severity, quality of life, endoscopic and histologic activity.Objectives: We intend to take full advantage of our expertise in EoE activity assessment to address the following aims in three inter-related projects:Project I: We will identify endpoints (symptom severity, quality of life, endoscopic and histologic activity), which physicians and patients consider relevant for use in clinical trials and observational studies.Project II: We will define cut-off values of the EEsAI instruments scores for categorical disease activity (remission, mild, moderate, and severe disease). Using these definitions, we will examine the relationship between EoE symptom severity, quality of life, endoscopic and histologic activity in adult EoE patients.Project III: We will compare the efficacy of continuous and episodic treatment with oral viscous suspension of budesonide in maintaining clinical remission over a 54-week period in a proof of concept study.Methods: For project I, we will convene an inter-disciplinary working group composed of physicians with EoE expertise, representatives of regulatory authorities and industry. Delphi rounds will be conducted to achieve consensus on the selection of endpoints for clinical trials. The preliminary results will be shared with patients, and their input will be gained using surveys and focus group interviews. This input will be integrated into the final recommendations. In project II, we will define cut-off values of EEsAI scores for categorical disease activity states and examine the relationship between patient-reported outcome measures (symptoms, quality of life) and physician-reported biologic measures (endoscopic and histologic activity) in 250 prospectively included adult EoE patients. The strength of associations will be examined using the Spearman rank correlation coefficient.In project III, we will conduct a randomized, single-blind, non-inferiority trial (proof of concept study) comparing the efficacy of episodic and continuous treatment with oral viscous suspension of budesonide in maintaining clinical remission over a 54-week period. The primary endpoint will be the symptom score. Secondary endpoints will be quality of life score and stricture formation. A margin of 5 will be defined for non-inferiority of the episodic compared to continuous treatment. A total of 80 patients (40 per treatment arm) will be recruited. Analysis will be by intention to treat. The selected endpoints and definitions of categorical disease activity states from project 1 and 2, respectively, will be used to interpret the results.Expected results and importance: The definition of therapeutic endpoints will undoubtedly facilitate the development of much-awaited therapies for EoE management. Furthermore, this project will add new and important evidence from a well-characterized cohort of EoE patients on the relationship between patient reported-outcomes and biologic measures of EoE activity. The results of the randomized trial will be useful in optimizing long-term pharmacological treatment strategies.